Rising prevalence of cancer, surging investments in research & development of genomic studies, and technological developments in genetic sequencing & target gene selection are impelling the growth of global cancer monoclonal antibodies market during.
According to the research report titled ‘Global Cancer Monoclonal Antibodies Market Size study, by Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies), by Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others), by Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others) and Regional Forecasts 2020-2027‘, available with Market Study Report LLC, global cancer monoclonal antibodies market was valued at USD 41.3 billion in 2019 and is expected to witness a CAGR of 11.3% during 2020-2027.
Rising prevalence of cancer, surging investments in research & development of genomic studies, and technological developments in genetic sequencing & target gene selection are impelling the growth of global cancer monoclonal antibodies market during.
Notably, laboratory-produced molecules, cancer monoclonal antibodies work as substitute antibodies to enhance, simulate, or restore the immune system's attack on cancer cells. They are used to treat different types of cancer, such as breast cancer, melanoma, brain cancer, and lung cancer, thus propelling global cancer monoclonal antibodies market outlook.
Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/2730772/
Amidst the COVID-19 outbreak, the pharma industry is more concerned about the development of the coronavirus vaccine. Hence, R&D activities for cancer monoclonal antibodies has taken a plunge, although the demand for cancer monoclonal antibodies is stable and as high as it was before the pandemic. On the contrary, strict regulatory guidelines and long duration of R&D with frequent failures in clinical trials may restrain global cancer monoclonal antibodies market scenario during the forecast period of 2020-2027.
Based on application spectrum, global cancer monoclonal antibodies industry is segmented into blood cancer, breast cancer, colorectal cancer, brain cancer, liver cancer and others. With regards to therapy type, the industry is bifurcated into bevacizumab (Avastin), trastuzumab (Herceptin), panitumumab (Vectibix), cetuximab (Erbitux), rituximab (Rituxan), and others. As per type, the market is segmented into chimeric antibodies, humanized antibodies, and murine antibodies.
Regionally, North America was the major revenue contributor for global cancer monoclonal antibodies market in the recent past, mainly due to increasing incidences of cancer and rising government investments for infection control & management in the region. Meanwhile, Asia Pacific market is anticipated to witness highest growth rate over 2020-2027, owing to rising government funding for cancer research & technology, followed by the presence of many leading companies in the region.
Major players operating in global cancer monoclonal antibodies industry include Amgen Inc., Spectrum Pharmaceuticals Inc., Merck & Co. Inc, F. Hoffmann-La Roche Ltd, Genmab A/S, Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Eli Lilly and Company, and GlaxoSmithKline PLC.
To access a sample pages of this report titled “Global Cancer Monoclonal Antibodies Market Size study, by Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies), by Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others), by Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others) and Regional Forecasts 2020-2027” in detail along with the table of contents, please click the link below:
https://www.marketstudyreport.com/reports/global-cancer-monoclonal-antibodies-market-size-research
Related Report:
Cancer Diagnostics Market, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026
The global cancer diagnostics market share has been depicting a substantial expansion since the last decade or so on account of the increasing cancer prevalence worldwide. Unhealthy diet patterns, sedentary lifestyles including smoking and extensive alcohol consumption, and rising obesity are majorly responsible for the upsurge in the number of cancer cases. According to the American Cancer Society, here will be an anticipated 1.8 million new cancer cases that would be diagnosed in 2020 and 606,520 deaths from cancer, in the United States alone. Latin America is anticipated to emerge as a lucrative growth ground for cancer diagnostics market, driven by the robust prevalence of cancer in the region. Latin America market is anticipated to cross USD 7.3 billion by 2026.
About US:
Market Study Report, LLC. is a hub for market intelligence products and services.
We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.
Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.
If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.
Contact Us:
Corporate Sales,
Market Study Report LLC
Phone: 1-302-273-0910
Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com